Therapeutic potential of arsenic trioxide with or without interferon-α for relapsed/refractory adult T-cell leukemia/lymphoma

Haematologica

Volumn 92, Issue 5, 2007, Pages 719-720

  Ishitsuka, Kenji ^a   Suzumiya, Junji ^a   Aoki, Mikiko ^a   Ogata, Kentaro ^b   Hara, Shuuji ^b   Tamura, Kazuo ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b FUKUOKA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ARSENIC TRIOXIDE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ETOPOSIDE; LACTATE DEHYDROGENASE; PEPLEOMYCIN; PIRARUBICIN; PREDNISOLONE; RECOMBINANT ALPHA INTERFERON; VINCRISTINE; ANTINEOPLASTIC AGENT; ORGANOARSENIC DERIVATIVE; OXIDE;

ADULT; AGED; ANEMIA; ARTICLE; CASE REPORT; COMBINATION CHEMOTHERAPY; CORRELATION ANALYSIS; DISEASE COURSE; DRUG SAFETY; FEMALE; FEVER; HUMAN; HUMAN CELL; HYPOKALEMIA; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MONOTHERAPY; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PILOT STUDY; QT PROLONGATION; RASH; SIDE EFFECT; T CELL LEUKEMIA; T CELL LYMPHOMA; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; CLINICAL TRIAL; DRUG EFFECT; LETTER; RECURRENT DISEASE; SALVAGE THERAPY; TUMOR CELL LINE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; CELL LINE, TUMOR; DISEASE PROGRESSION; FEMALE; HUMANS; INTERFERON-ALPHA; LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED; MALE; OXIDES; RECURRENCE; SALVAGE THERAPY; THROMBOCYTOPENIA;

EID: 34447316759     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10703     Document Type: Article

References (10)

1. Ishitsuka K, Hanada S, Suzuki S, Utsunomiya A, Chyuman Y, Takeuchi S, et al. Arsenic trioxide inhibits growth of human T-cell leukaemia virus type I infected T-cell lines more effectively than retinoic acids. Br J Haematol 1998;103:721-8.
2. Bazarbachi A, El-Sabban ME, Nasr R, Quignon F, Awaraji C, Kersual J, et al. Arsenic trioxide and interferon-α synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood 1999;93:278-83.
3. Ishitsuka K, Hanada S, Uozumi K, Utsunomiya A, Arima T. Arsenic trioxide and the growth of human T-cell leukemia virus type I infected T-cell lines. Leuk Lymphoma 2000;37:649-55.
4. Hermine O, Dombret H, Poupon J, Amulf B, Lefrere F, Rousselot P, et al. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. Hematol J 2004;5:130-4.
5. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol 1991;79:428-37.
6. Shimoyama M. Chemotherapy of ATL. In: Takatsuki K, ed. Adult T-Cell Leukemia. Oxford: Oxford University Press; 1994. p. 221-37.
7. Ishitsuka K, Ikeda R, Utsunomiya A, Uozumi K, Hanada S, Suzuki S, et al. Arsenic trioxide induces apoptosis in HTLV-I infected T-cell lines and fresh adult T-cell leukemia cells through CD95 or tumor necrosis factor alpha receptor independent caspase activation. Leuk Lymphoma 2002; 43:1107-14.
8. Yamada Y, Tomonaga M, Fukuda H, Hanada S, Utsunomiya A, Tara M, et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol 2001;113:375-82.
9. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocyte leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89: 3354-60.
10. Ishitsuka K, Shirahashi A, Iwao Y, Shishime M, Takamatsu Y, Takatsuka Y, et al. Bone marrow necrosis in a patient with acute promyelocyte leukemia during re-induction therapy with arsenic trioxide. Eur J Haematol 2004;72:280-4.